Skip to main content
Update Location

My Location

Update your location to show providers, locations, and services closest to you.

Enter a zip code
Select a campus/region

BT015: Blood-Brain Barrier Disruption (BBBD) Liquid Biopsy in Subjects With GlioBlastoma Brain Tumor

  • Status
    Accepting Candidates
  • Age
    18 Years - 80 Years
  • Sexes
  • Healthy Volunteers


The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects with suspected Glioblastoma brain tumors


This is a prospective, multi-center, pivotal clinical trial to evaluate the safety and efficacy of targeted blood brain barrier disruption using Exablate Model 4000 Type 2 for liquid biopsy in subjects with suspected Glioblastoma brain tumors. The study will be conducted at up to 25 centers in the US.


Full study title A Pivotal Study to Evaluate the Safety and Effectiveness of Exablate Model 4000 using Microbubble Resonators to Temporarily Mediate Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with Glioblastoma Brain Tumors
Protocol number OCR44344 ID NCT05383872
Phase N/A


Inclusion Criteria:

  1. Male or Female subjects18-80 years of age who are able and willing to give informed consent, or whose legally authorized representative is willing to consent on their behalf

  2. Subjects with stereotactically-targetable suspected new or recurrent glioblastoma tumor on pre-operative brain imaging scans

  3. Subjects that are scheduled, or will be scheduled within 4 weeks, for surgical resection or biopsy per standard clinical tumor care

  4. Karnofsky Performance Score >70

  5. Able to communicate sensations during the Exablate BBBD procedure

Exclusion Criteria:

  1. Subjects with inoperable tumors (e.g., tumor originating from the deep midline, thalamus, midbrain, cerebellum or brainstem)

  2. Multifocal tumors

  3. Tumor morphology or other imaging findings that precludes the ability to sonicate the tumor volume (including significant tumor volume outside the treatment envelope or tumor volume that exceeds the maximum sonication volume allowed, i.e. currently 110 ccs at the treatment volume level). Concern for adequate tumor coverage by sonication based on tumor morphology should be discussed with the Sponsor.

  4. MRI or clinical findings of:

    1. Active or chronic infection(s) or inflammatory processes

    2. Acute or chronic hemorrhages, specifically any lobar microbleeds, and no siderosis, amyloid angiopathy, or macro-hemorrhages

    3. Intracranial thrombosis, vascular malformation, cerebral aneurysm or vasculitis

  5. MR non-compatible metallic implants in the skull or the brain or the presence of unknown MR unsafe devices

  6. Significant cardiac disease or unstable hemodynamic status

    1. Documented myocardial infarction within six months of enrollment

    2. Unstable angina on medication

    3. Unstable or worsening congestive heart failure

    4. Documented left ventricular ejection fraction below the lower limit of normal

    5. History of a hemodynamically unstable cardiac arrhythmia

    6. Cardiac pacemaker

  7. Uncontrolled hypertension (systolic > 180 and diastolic BP > 120 on medication)

  8. Undergoing anti-coagulant or anti-platelet therapy, or using medications known to increase risk of hemorrhage within washout period prior to treatment (i.e., antiplatelet or vitamin K inhibitor anticoagulants within 7 days, non-vitamin K inhibitor anticoagulants within 72 hours, or heparin-derived compounds within 48 hours of treatment).

  9. History of bleeding disorder, coagulopathy or a history of spontaneous hemorrhage or evidence of increased risk of bleeding

  10. Abnormal coagulation profile (Platelets < 80,000, PT >14, PTT >36, or INR > 1.3)

  11. Known cerebral or systemic vasculopathy

  12. Significant depression and at potential risk of suicide

  13. Known sensitivity/allergy to gadolinium or DEFINITY/DEFINITY RT,

  14. Active seizures despite medication treatment (defined as >1 seizure per week) which

could be worsened by disruption of the blood brain barrier

  1. Active drug or alcohol disorder which have a higher risk for seizures, infection

and/or poor executive functioning

  1. Known positive HIV status, which can lead to increased entry of HIV into the brain

parenchyma leading to HIV encephalitis

  1. Potential blood-borne infections which can lead to increased entry to brain parenchyma

leading to meningitis or brain abscess

  1. Any contraindications to MRI scanning, including:

  2. Large subjects not fitting comfortably into the scanner

  3. Difficulty lying supine and still for up to 3 hours in the MRI unit or claustrophobia

  4. Impaired renal function with estimated glomerular filtration rate

Lead researcher

Participate in a study

Here are some general steps to consider when participating in a research study:

  1. Step

    Contact the research team

    Call or email the research team listed within the specific clinical trial or study to let them know that you're interested. A member of the research team, such as the researcher or study coordinator, will be available to tell you more about the study and to answer any questions or concerns you may have.

    Primary contact

  2. Step

    Get screened to confirm eligibility

    You may be asked to take part in prescreening to make sure you are eligible for a study. The prescreening process ensures it is safe for you to participate. During the prescreening process, you will be asked some questions and you may also be asked to schedule tests or procedures to confirm your eligibility.

  3. Step

    Provide your consent to participate

    If you are eligible and want to join the clinical trial or study, a member of the research team will ask for your consent to participate. To give consent, you will be asked to read and sign a consent form for the study. This consent form explains the study's purpose, procedures, risks, benefits and provides other important information, such as the study team's contact information.

  4. Step


    If you decide to participate in a clinical trial or study, the research team will keep you informed of the study requirements and what you will need to do to throughout the study. For some trials or studies, your health care provider may work with the research team to ensure there are no conflicts with other medications or treatments.